Cargando…
Clinical Response to Valproate in Patients with Migraine
BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring sys...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063874/ https://www.ncbi.nlm.nih.gov/pubmed/27819417 http://dx.doi.org/10.3988/jcn.2016.12.4.468 |
_version_ | 1782460051511836672 |
---|---|
author | Ichikawa, Mizuki Katoh, Hirotaka Kurihara, Tatsuya Ishii, Masakazu |
author_facet | Ichikawa, Mizuki Katoh, Hirotaka Kurihara, Tatsuya Ishii, Masakazu |
author_sort | Ichikawa, Mizuki |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring system for predicting the clinical response to prophylactic therapy. METHODS: We investigated clinical factors from the medical records of 95 consistent responders (CRs) and 24 inconsistent responders (IRs) to valproate. RESULTS: Multivariate stepwise logistic regression analysis revealed that a history of hyperlipidemia and hay fever and the complication of depression or other psychiatric disorder were significant factors that independently contributed to a negative response, with odds ratios of 6.024 [no vs. yes; 95% confidence interval (CI)=1.616–22.222], 2.825 (no vs. yes; 95% CI=1.046–7.634), and 2.825 (no vs. yes; 95% CI=1.052–7.576), respectively. A predictive index (PI) of the clinical response to valproate in patients with migraine was calculated using the regression coefficients of these three factors as an integer, and the index was significantly higher for IRs than for CRs (1.46±1.10 vs. 0.69±0.74, mean±SD, p<0.001). CONCLUSIONS: The obtained PI may represent an appropriate scoring system for predicting the responses in these patients. |
format | Online Article Text |
id | pubmed-5063874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Neurological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-50638742016-10-17 Clinical Response to Valproate in Patients with Migraine Ichikawa, Mizuki Katoh, Hirotaka Kurihara, Tatsuya Ishii, Masakazu J Clin Neurol Original Article BACKGROUND AND PURPOSE: Valproate is used as a prophylactic drug for migraine, but it is not be effective in all patients. We used medical records to investigate which clinical factors affected the response to valproate in patients with migraine as an original headache, and established a scoring system for predicting the clinical response to prophylactic therapy. METHODS: We investigated clinical factors from the medical records of 95 consistent responders (CRs) and 24 inconsistent responders (IRs) to valproate. RESULTS: Multivariate stepwise logistic regression analysis revealed that a history of hyperlipidemia and hay fever and the complication of depression or other psychiatric disorder were significant factors that independently contributed to a negative response, with odds ratios of 6.024 [no vs. yes; 95% confidence interval (CI)=1.616–22.222], 2.825 (no vs. yes; 95% CI=1.046–7.634), and 2.825 (no vs. yes; 95% CI=1.052–7.576), respectively. A predictive index (PI) of the clinical response to valproate in patients with migraine was calculated using the regression coefficients of these three factors as an integer, and the index was significantly higher for IRs than for CRs (1.46±1.10 vs. 0.69±0.74, mean±SD, p<0.001). CONCLUSIONS: The obtained PI may represent an appropriate scoring system for predicting the responses in these patients. Korean Neurological Association 2016-10 2016-09-30 /pmc/articles/PMC5063874/ /pubmed/27819417 http://dx.doi.org/10.3988/jcn.2016.12.4.468 Text en Copyright © 2016 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ichikawa, Mizuki Katoh, Hirotaka Kurihara, Tatsuya Ishii, Masakazu Clinical Response to Valproate in Patients with Migraine |
title | Clinical Response to Valproate in Patients with Migraine |
title_full | Clinical Response to Valproate in Patients with Migraine |
title_fullStr | Clinical Response to Valproate in Patients with Migraine |
title_full_unstemmed | Clinical Response to Valproate in Patients with Migraine |
title_short | Clinical Response to Valproate in Patients with Migraine |
title_sort | clinical response to valproate in patients with migraine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063874/ https://www.ncbi.nlm.nih.gov/pubmed/27819417 http://dx.doi.org/10.3988/jcn.2016.12.4.468 |
work_keys_str_mv | AT ichikawamizuki clinicalresponsetovalproateinpatientswithmigraine AT katohhirotaka clinicalresponsetovalproateinpatientswithmigraine AT kuriharatatsuya clinicalresponsetovalproateinpatientswithmigraine AT ishiimasakazu clinicalresponsetovalproateinpatientswithmigraine |